Last reviewed · How we verify
AMINOPHYLLINE
At a glance
| Generic name | AMINOPHYLLINE |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 1940 |
Approved indications
Common side effects
- Seizures
- Vomiting
- Diarrhea
- Tremors
- Sinus tachycardia
- Disorientation
- Hypokalemia
- Hyperglycemia
- Abdominal Pain
- Rhabdomyolysis
- Multifocal atrial tachycardia
- Ventricular premature beats
Key clinical trials
- Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures (NA)
- A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (PHASE3)
- Prevention of Cisplatin-induced Nephrotoxicity (PHASE2, PHASE3)
- Theophylline Prophylaxis During Hypothermia to Limit Neonatal Nephron Damage (PHASE1, PHASE2)
- Heart Rhythm Changes in Patients With Atrial Fibrillation After Cardiopulmonary Bypass: a Retrospective Analysis
- Intra-ureteric Aminophylline Instillation on Flexible Ureteroscopy Procedure (NA)
- Timing of Aminophylline and Recovery in Pediatric Ambulatory Surgery (PHASE3)
- Reversal of Complete Heart Block With Aminophylline in Inferior Wall Myocardial Infarction Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMINOPHYLLINE CI brief — competitive landscape report
- AMINOPHYLLINE updates RSS · CI watch RSS